Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/93094
標題: The application of the subunit vaccine against infectious bursal disease in chickens with maternal antibody
雞傳染性華氏囊病次單位疫苗在具母源抗體雞隻中之應用
作者: 卓晉丞
Chin-Cheng Cho
關鍵字: 論文
中興大學
Thesis
National Chung Hsing University
引用: 朱廣中。2010。雞傳染性華氏囊病及傳染性支氣管炎雙價疫苗之研發。碩士論文。國立中興大學微生物暨公共衛生學研究所。台中。 吳義與,陳自昌,姚韻琴。1983。傳染性華氏囊炎兔疫之研究。中華獸醫誌。9:125-132。 姚中慧,張秀梅,蔡向榮。2004。1998年台灣地區種雞與蛋雞之重要傳染病抗體調查。臺灣獸醫誌。30:307-314。 廖君儀。2012。大腸桿菌表現雞傳染性華氏囊病類病毒顆粒產量及保護效力之提升。碩士論文。國立中興大學微生物暨公共衛生學研究所。台中。 蔡向榮,呂榮修。1993。1992年台灣雞傳染性華氏囊病大流行之疫情分析。中華獸醫誌。19:249-258。 蔡向榮,林地發,陳茂振,張文章,呂榮修,宋華聰。1995。雞傳染性華氏囊病移行抗體之分布與消長及其與疫苗免疫之關係。中華獸醫誌。21:223-231。 Abdel-Alim, G.A., Saif, Y.M., 2001. Detection and persistence of infectious bursal disease virus in specific-pathogen-free and commercial broiler chickens. Avian Dis. 45, 646-654. Aguilar, J.C., Rodriguez, E.G., 2007. Vaccine adjuvants revisited. Vaccine. 25, 3752-3762. Arnold, M., Durairaj, V., Mundt, E., Schulze, K., Breunig, K.D., Behrens, S.E., 2012. Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit. PLoS One. 7, e42870. Arvin, A.M. 2000. Vaccines, Viral, In: Lederberg, J. (Ed.) Encyclopedia of microbiology, 2nd ed. Academic Press, San Diego, 779-787. Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S., Ganne, V., 2002. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines. 1, 111-118. Aucouturier, J., Dupuis, L., Ganne, V., 2001. Adjuvants designed for veterinary and human vaccines. Vaccine. 19, 2666-2672. Barnett, P.V., Pullen, L., Williams, L., Doel, T.R., 1996. International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Vaccine. 14, 1187-1198. Baxendale, W., Lutticken, D., 1981. Results of field trials with an inactivated Gumboro vaccine. Dev. Biol. Stand. 51, 211-219. Bayliss, C.D., Peters, R.W., Cook, J.K., Reece, R.L., Howes, K., Binns, M.M., Boursnell, M.E., 1991. A recombinant fowlpox virus that expresses the VP2 antigen of infectious bursal disease virus induces protection against mortality caused by the virus. Arch. Virol. 120, 193-205. Becht, H., Muller, H., Muller, H.K., 1988. Comparative studies on structural and antigenic properties of two serotypes of infectious bursal disease virus. J. Gen. Virol. 69, 631-640. Benton, W.J., Cover, M.S., Rosenberger, J.K., Lake, R.S., 1967. Physicochemical properties of the infectious bursal agent (IBA). Avian Dis. 11, 438-445. Berg, T.P., 2000. Acute infectious bursal disease in poultry: a review. Avian Pathol. 29, 175-194. Berg, T.P., Gonze, M., Meulemans, G., 1991. Acute infectious bursal disease in poultry: Isolation and characterisation of a highly virulent strain. Avian Pathol. 20, 133-143. Bessette, P.H., Aslund, F., Beckwith, J., Georgiou, G., 1999. Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm.pdf>. Proc. Natl. Acad. Sci. U. S. A. 96, 13703-13708. Beug, H., Muller, H., Grieser, S., Doederlein, G., Graf, T., 1981. Hematopoietic cells transformed in vitro by REVT avian reticuloendotheliosis virus express characteristics of very immature lymphoid cells. Virology. 115, 295-309. Birghan, C., Mundt, E., Gorbalenya, A.E., 2000. A non-canonical lon proteinase lacking the ATPase domain employs the ser-Lys catalytic dyad to exercise broad control over the life cycle of a double-stranded RNA virus. EMBO J. 19, 114-123. Blanchard, P., Mahe, D., Cariolet, R., Keranflec'h, A., Baudouard, M.A., Cordioli, P., Albina, E., Jestin, A., 2003. Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins. Vaccine. 21, 4565-4575. Block, H., Meyer-Block, K., Rebeski, D.E., Scharr, H., de Wit, S., Rohn, K., Rautenschlein, S., 2007. A field study on the significance of vaccination against infectious bursal disease virus (IBDV) at the optimal time point in broiler flocks with maternally derived IBDV antibodies. Avian Pathol. 36, 401-409. Boot, H.J., ter Huurne, A.A., Hoekman, A.J., Peeters, B.P., Gielkens, A.L., 2000. Rescue of very virulent and mosaic infectious bursal disease virus from cloned cDNA: VP2 is not the sole determinant of the very virulent phenotype. J. Virol. 74, 6701-6711. Bottcher, B., Kiselev, N.A., Stel'Mashchuk, V.Y., Perevozchikova, N.A., Borisov, A.V., Crowther, R.A., 1997. Three-dimensional structure of infectious bursal disease virus determined by electron cryomicroscopy. J. Virol. 71, 325-330. Brandt, M., Yao, K., Liu, M., Heckert, R.A., Vakharia, V.N., 2001. Molecular determinants of virulence, cell tropism, and pathogenic phenotype of infectious bursal disease virus. J. Virol. 75, 11974-11982. Brown, F., 1986. The Classification and Nomenclature of Viruses: Summary of Results of Meetings of the International Committee on Taxonomy of Viruses in Sendai, September 1984. Intervirology. 25, 141-143. Brown, M.D., Green, P., Skinner, M.A., 1994. VP2 sequences of recent European 'very virulent' isolates of infectious bursal disease virus are closely related to each other but are distinct from those of 'classical' strains. J. Gen. Virol. 75, 675-680. Bumstead, N., Reece, R.L., Cook, J.K., 1993. Genetic differences in susceptibility of chicken lines to infection with infectious bursal disease virus. Poult. Sci. 72, 403-410. Bunn, T.O. 1993. Vaccine adjuvants and carriers, In: Peters, A.R. (Ed.) Vaccines for veterinary applications. Butterworth-Heinemann, Oxford, 295-306. Burkhardt, E., Muller, H., 1987. Susceptibility of chicken blood lymphoblasts and monocytes to infectious bursal disease virus (IBDV). Arch. Virol. 94, 297-303. Butler, N.R., Voyce, M.A., Burland, W.L., Hilton, M.L., 1969. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Br. Med. J. 1, 663-666. Byars, N.E., Allison, A.C. 1990. Immunologic adjuvants: general properties, advantages, and limitations, In: Zola, H. (Ed.) Laboratory Methods in Immunology. 39-51. Cao, Y.C., Yeung, W.S., Law, M., Bi, Y.Z., Leung, F.C., Lim, B.L., 1998. Molecular characterization of seven Chinese isolates of infectious bursal disease virus: classical, very virulent, and variant strains. Avian Dis. 42, 340-351. Chalmers, W.S., 2006. Overview of new vaccines and technologies. Vet. Microbiol. 117, 25-31. Chettle, N., Stuart, J.C., Wyeth, P.J., 1989. Outbreak of virulent infectious bursal disease in East Anglia. Vet. Rec. 125, 271-272. Chettle, N.J., Eddy, R.K., Wyeth, P.J., 1985. Comparison of virus neutralizing and precipitating antibodies to infectious bursal disease virus and their effect on susceptibility to challenge. Br. Vet. J. 141, 146-150. Cosgrove, A.S., 1962. An apparently new disease of chickens-avian nephrosis. Avian Dis. 6, 385-389. Coulibaly, F., Chevalier, C., Gutsche, I., Pous, J., Navaza, J., Bressanelli, S., Delmas, B., Rey, F.A., 2005. The birnavirus crystal structure reveals structural relationships among icosahedral viruses. Cell. 120, 761-772. Dobos, P., Hill, B.J., Hallett, R., Kells, D.T., Becht, H., Teninges, D., 1979. Biophysical and biochemical characterization of five animal viruses with bisegmented double-stranded RNA genomes. J. Virol. 32, 593-605. Donly, B.C., Edgar, C.D., Adamski, F.M., Tate, W.P., 1990. Frameshift autoregulation in the gene for Escherichia coli release factor 2: partly functional mutants result in frameshift enhancement. Nucleic Acids Res. 18, 6517-6522. Ellis, R.W., 1999. New technologies for making vaccines. Vaccine. 17, 1596-1604. Escaffre, O., Le Nouen, C., Amelot, M., Ambroggio, X., Ogden, K.M., Guionie, O., Toquin, D., Muller, H., Islam, M.R., Eterradossi, N., 2013. Both genome segments contribute to the pathogenicity of very virulent infectious bursal disease virus. J. Virol. 87, 2767-2780. Estes, M.K., Ball, J.M., Crawford, S.E., O'Neal, C., Opekun, A.A., Graham, D.Y., Conner, M.E., 1997. Virus-like particle vaccines for mucosal immunization. Adv. Exp. Med. Biol. 412, 387-395. Eterradossi, N., Arnauld, C., Toquin, D., Rivallan, G., 1998. Critical amino acid changes in VP2 variable domain are associated with typical and atypical antigenicity in very virulent infectious bursal disease viruses. Arch. Virol. 143, 1627-1636. Eterradossi, N., Picault, J.P., Drouin, P., Guittet, M., L'Hospitalier, R., Bennejean, G., 1992. Pathogenicity and preliminary antigenic characterization of six infectious bursal disease virus strains isolated in France from acute outbreaks. Zentralbl Veterinarmed B. 39, 683-691. Fahey, K.J., Chapman, A.J., Macreadie, I.G., Vaughan, P.R., McKern, N.M., Skicko, J.I., Ward, C.W., Azad, A.A., 1991. A recombinant subunit vaccine that protects progeny chickens from infectious bursal disease. Avian Pathol. 20, 447-460. Fahey, K.J., Crooks, J.K., Fraser, R.A., 1987. Assessment by ELISA of passively acquired protection against infectious bursal disease virus in chickens. Aust. Vet. J. 64, 203-207. Fahey, K.J., Erny, K., Crooks, J., 1989. A conformational immunogen on VP-2 of infectious bursal disease virus that induces virus-neutralizing antibodies that passively protect chickens. J. Gen. Virol. 70, 1473-1481. Freund, J., 1956. The mode of action of immunologic adjuvants. Bibl. Tuberc. 10, 130-148. Freund, J., Thomson, K.J., Hough, H.B., Sommer, H.E., Pisani, T.M., 1948. Antibody formation and sensitization with the aid of adjuvants. J. Immunol. 60, 383-398. Freunds, J., Casals, J., Hosmer, E.P., 1937. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 37, 509-513. Fussell, L.W., 1998. Poultry industry strategies for control of immunosuppressive diseases. Poult. Sci. 77, 1193-1196. Gharaibeh, S., Mahmoud, K., 2013. Decay of maternal antibodies in broiler chickens. Poult. Sci. 92, 2333-2336. Glenney, A.T., Pope, C.G., Waddington, H., Wallace, U., 1926. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 29, 38-39. Gupta, R.K., Rost, B.E., Relyveld, E., Siber, G.R. 1995. Adjuvant Properties of Aluminium and Calcium Compounds, In: Powell, M.F., Newman, M.J. (Eds.) Vaccine Design: the Subunit and Adjuvant Approach. Plenum Press, New York, 229-248. Heine, H.G., Boyle, D.B., 1993. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch. Virol. 131, 277-292. Hilleman, M.R., Woodhour, A.F., Friedman, A., Phelps, A.H., 1972. Studies for safety of adjuvant 65. Ann. Allergy. 30, 477-483. Hioe, C.E., Qiu, H., Chend, P.D., Bian, Z., Li, M.L., Li, J., Singh, M., Kuebler, P., McGee, P., O'Hagan, D., Zamb, T., Koff, W., Allsopp, C., Wang, C.Y., Nixon, D.F., 1996. Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine. 14, 412-418. Hirai, K., Kunihiro, K., Shimakura, S., 1979. Characterization of Immunosuppression in chickens by infectious bursal disease virus. Avian Dis. 23, 950-965. Hoiseth, S.K. 2000. Vaccines, Bacterial, In: Lederberg, J. (Ed.) Encyclopedia of microbiology, 2nd ed. Academic Press, San Diego, 767-778. Hudson, P.J., McKern, N.M., Power, B.E., Azad, A.A., 1986. Genomic structure of the large RNA segment of infectious bursal disease virus. Nucleic Acids Res. 14, 5001-5012. Ikuta, N., El-Attrache, J., Villegas, P., Garcia, E.M., Lunge, V.R., Fonseca, A.S., Oliveira, C., Marques, E.K., 2001. Molecular characterization of Brazilian infectious bursal disease viruses. Avian Dis. 45, 297-306. Irigoyen, N., Garriga, D., Navarro, A., Verdaguer, N., Rodriguez, J.F., Caston, J.R., 2009. Autoproteolytic activity derived from the infectious bursal disease virus capsid protein. J. Biol. Chem. 284, 8064-8072. Jackwood, D.H., Saif, Y.M., 1987. Antigenic diversity of infectious bursal disease viruses. Avian Dis. 31, 766-770. Jackwood, D.J., Sommer, S.E., 1999. Restriction fragment length polymorphisms in the VP2 gene of infectious bursal disease viruses from outside the United States. Avian Dis. 43, 310-314. Jackwood, D.J., Sommer, S.E., 2002. Identification of infectious bursal disease virus quasispecies in commercial vaccines and field isolates of this double-stranded RNA virus. Virology. 304, 105-113. Jagadish, M.N., Staton, V.J., Hudson, P.J., Azad, A.A., 1988. Birnavirus precursor polyprotein is processed in Escherichia coli by its own virus-encoded polypeptide. J. Virol. 62, 1084-1087. Jang, S.I., Lillehoj, H.S., Lee, S.H., Lee, K.W., Lillehoj, E.P., Bertrand, F., Dupuis, L., Deville, S., 2011. Mucosal immunity against Eimeria acervulina infection in broiler chickens following oral immunization with profilin in Montanide adjuvants. Exp. Parasitol. 129, 36-41. Jang, S.I., Lillehoj, H.S., Lee, S.H., Lee, K.W., Lillehoj, E.P., Hong, Y.H., An, D.J., Jeong, W., Chun, J.E., Bertrand, F., Dupuis, L., Deville, S., Arous, J.B., 2012. Vaccination with Clostridium perfringens recombinant proteins in combination with Montanide ISA 71 VG adjuvant increases protection against experimental necrotic enteritis in commercial broiler chickens. Vaccine. 30, 5401-5406. Johnson, D.C., Lukert, P.D., Page, R.K., 1980. Field studies with convalescent serum and infectious bursal disease vaccine to control turkey coryza. Avian Dis. 24, 386-392. Jungmann, A., Nieper, H., Muller, H., 2001. Apoptosis is induced by infectious bursal disease virus replication in productively infected cells as well as in antigen-negative cells in their vicinity. J. Gen. Virol. 82, 1107-1115. Kane, J.F., 1995. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr. Opin. Biotechnol. 6, 494-500. Katayama, S., Oda, K., Ohgitani, T., 2000. Influence of antigenic forms and adjuvants on protection against a lethal infection of Aujeszky's disease virus. Vaccine. 19, 54-58. Kim, I.J., You, S.K., Kim, H., Yeh, H.Y., Sharma, J.M., 2000. Characteristics of bursal T lymphocytes induced by infectious bursal disease virus. J. Virol. 74, 8884-8892. Kim, S.J., 1992. Infectious bursal disease with high mortalities in Korea. Proc. of Int. Seminar Prev. Cont. of Poult. Dis., Bangkok, Thailand. 54-73. Le Moignic, P., 1916. Application to man of vaccines consisting of emulsions in fatty substances (lipo-vaccines). Compt. Rend. Soc. Biol. 29, 352-358. Lee, L.H., Yu, S.L., Shieh, H.K., 1992. Detection of infectious bursal disease virus infection using the polymerase chain reaction. J. Virol. Meth. 40, 243-253. Lejal, N., Da Costa, B., Huet, J.C., Delmas, B., 2000. Role of Ser-652 and Lys-692 in the protease activity of infectious bursal disease virus VP4 and identification of its substrate cleavage sites. J. Gen. Virol. 81, 983-992. Letzel, T., Coulibaly, F., Rey, F.A., Delmas, B., Jagt, E., van Loon, A.A., Mundt, E., 2007. Molecular and structural bases for the antigenicity of VP2 of infectious bursal disease virus. J. Virol. 81, 12827-12835. Lin, T.C., Lee, R.C.T., 1983. An overall report on the development of a highly safe and potent lapinized hog cholera virus strain for hog cholera control in Taiwan. NSC special publication No. 5. National Science Council, Taipei. Liu, M., Vakharia, V.N., 2004. VP1 protein of infectious bursal disease virus modulates the virulence in vivo. Virology. 330, 62-73. Lombardo, E., Maraver, A., Espinosa, I., Fernandez-Arias, A., Rodriguez, J.F., 2000. VP5, the nonstructural polypeptide of infectious bursal disease virus, accumulates within the host plasma membrane and induces cell lysis. Virology. 277, 345-357. Lowris, D.B., Whalen, R.G., 2000. DNA Vaccines: Methods and Protocols. Humana Press Inc., Totowa, New Jersey, U. S. A. Lu, Y.L., Shieh, H.K., 1983. Infectious bursal disease in Taiwan. J. Chin. Soc. Vet. Sci. 9, 61-66. Lucio, B., Hitchner, S.B., 1978. Infectious bursal disease emulsified vaccine: effect upon neutralizing-antibody levels in the dam and subsequent protection of the progeny. Avian Dis. 23, 466-477. Lucio, B., Hitchner, S.B., 1979. Infectious Bursal Disease Emulsified Vaccine: Effect upon Neutralizing-Antibody Levels in the Dam and Subsequent Protection of the Progeny. Avian Dis. 23, 466-478. Lukert, P.D., Saif, Y.M. 2003. Infectious bursal disease, In: Saif, Y.M., Barnes, H.J., Glisson, J.R., Fadly, A.M., McDougald, L.R., Swayne, D.E. (Eds.) Disease of poultry 11th ed. Iowa State University Press, Ames, 161-180. Luque, D., Saugar, I., Rodriguez, J.F., Verdaguer, N., Garriga, D., Martin, C.S., Velazquez-Muriel, J.A., Trus, B.L., Carrascosa, J.L., Caston, J.R., 2007. Infectious bursal disease virus capsid assembly and maturation by structural rearrangements of a transient molecular switch. J. Virol. 81, 6869-6878. Lutticken, D., 1997. Viral diseases of the immune system and strategies to control infectious bursal disease by vaccination. Acta. Vet. Hung. 45, 239-249. Macreadie, I.G., Vaughan, P.R., Chapman, A.J., McKern, N.M., Jagadish, M.N., Heine, H.G., Ward, C.W., Fahey, K.J., Azad, A.A., 1990. Passive protection against infectious bursal disease virus by viral VP2 expressed in yeast. Vaccine. 8, 549-552. Mahgoub, H.A., Bailey, M., Kaiser, P., 2012. An overview of infectious bursal disease. Arch. Virol. 157, 2047-2057. Martinez-Torrecuadrada, J.L., Saubi, N., Pages-Mante, A., Caston, J.R., Espuna, E., Casal, J.I., 2003. Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines. Vaccine. 21, 3342-3350. Mazariegos, L.A., Lukert, P.D., Brown, J., 1990. Pathogenicity and immunosuppressive properties of infectious bursal disease 'intermediate' strains. Avian Dis. 34, 203-208. McFerran, J.B., McNulty, M.S., McKillop, E.R., Connor, T.J., McCracken, R.M., Collins, D.S., Allan, G.M., 1980. Isolation and serological studies with infectious bursal disease viruses from fowl, turkeys and ducks: demonstration of a second serotype. Avian Pathol. 9, 395-404. McGeoch, D.J., Pringle, C.R., Wickner, R.B. 2000. VIIth Report of the ICTV (San Diego, Academic Press). McIlroy, S.G., Goodall, E.A., Bruce, D.W., McCracken, R.M., McNulty, M.S., 1992. The cost benefit of vaccinating broiler flocks against subclinical infectious bursal disease. Avian Pathol. 21, 65-76. Meeusen, E.N., Walker, J., Peters, A., Pastoret, P.P., Jungersen, G., 2007. Current status of veterinary vaccines. Clin. Microbiol. Rev. 20, 489-510, table of contents. Meulemans, G., Halen, P., 1982. Efficacy of some disinfectants against infectious bursal disease virus and avian reovirus. Vet. Rec. 111, 412-413. Moir, D.T., Dumais, D.R., 1987. Glycosylation and secretion of human alpha-1-antitrypsin by yeast. Gene. 56, 209-217. Mottagui-Tabar, S., Bjornsson, A., Isaksson, L.A., 1994. The second to last amino acid in the nascent peptide as a codon context determinant. EMBO J. 13, 249-257. Muller, H., 1986. Replication of infectious bursal disease virus in lymphoid cells. Arch. Virol. 87, 191-203. Muller, H., Islam, M.R., Raue, R., 2003. Research on infectious bursal disease-the past, the present and the future. Vet. Microbiol. 97, 153-165. Muller, H., Mundt, E., Eterradossi, N., Islam, M.R., 2012. Current status of vaccines against infectious bursal disease. Avian Pathol. 41, 133-139. Muller, H., Scholtissek, C., Becht, H., 1979. The genome of infectious bursal disease virus consists of two segments of double-stranded RNA. J. Virol. 31, 584-589. Mundt, E., Beyer, J., Muller, H., 1995. Identification of a novel viral protein in infectious bursal disease virus-infected cells. J. Gen. Virol. 76 ( Pt 2), 437-443. Murphy, F.A., Gibbs, E.P.J., Horzinek, M.C., Studdert, M.J., 1999. Veterinary Virology, 3rd edn. Academic Press, London. Naqi, S.A., Marquez, B., Sahin, N., 1983. Maternal antibody and its effect on infectious bursal disease immunization. Avian Dis. 27, 623-631. Nick, H., Cursiefen, D.,Becht, H., 1976. Structural and growth characteristics of infectious bursal disease virus. J. Virol. 18, 881-890. Nieper, H., Muller, H., 1996. Susceptibility of chicken lymphoid cells to infectious bursal disease virus does not correlate with the presence of specific binding sites. J. Gen. Virol. 77 ( Pt 6), 1229-1237. Nieper, H., Muller, H., 1998. Rapid preparation of plasma membranes from avian lymphoid cells and fibroblasts for virus binding studies. J. Virol. Meth. 72, 153-162. Novy, R., Drott, D., Yaeger, K., Mierendorf, R., 2001. Overcoming the codon bias of E. coli for enhanced protein expression. inNovations. 1-3. Ogawa, M., Yamaguchi, T., Setiyono, A., Ho, T., Matsuda, H., Furusawa, S., Fukushi, H., Hirai, K., 1998. Some characteristics of a cellular receptor for virulent infectious bursal disease virus by using flow cytometry. Arch. Virol. 143, 2327-2341. Oppling, V., Muller, H., Becht, H., 1991. Heterogeneity of the antigenic site responsible for the induction of neutralizing antibodies in infectious bursal disease virus. Arch. Virol. 119, 211-223. Paulson, J.C., Colley, K.J., 1989. Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation. J. Biol. Chem. 264, 17615-17618. Petek, M., D'Aprile, P.N., Cancellotti, F., 1973. Biological and physico-chemical properties of the infectious bursal disease virus (IBDV). Avian Pathol. 2, 135-152. Phenix, K.V., Wark, K., Luke, C.J., Skinner, M.A., Smyth, J.A., Mawhinney, K.A., Todd, D., 2001. Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development. Vaccine. 19, 3116-3123. Pitcovski, J., Gutter, B., Gallili, G., Goldway, M., Perelman, B., Gross, G., Krispel, S., Barbakov, M., Michael, A., 2003. Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens. Vaccine. 21, 4736-4743. Potter, M., Boyce, C.R., 1962. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature. 193, 1086-1087. Rautenschlein, S., Kraemer, C., Vanmarcke, J., Montiel, E., 2005. Protective efficacy of intermediate and intermediate plus infectious bursal disease virus (IBDV) vaccines against very virulent IBDV in commercial broilers. Avian Dis. 49, 231-237. Rautenschlein, S., Yeh, H.Y., Njenga, M.K., Sharma, J.M., 2002a. Role of intrabursal T cells in infectious bursal disease virus (IBDV) infection: T cells promote viral clearance but delay follicular recovery. Arch. Virol. 147, 285-304. Rautenschlein, S., Yeh, H.Y., Sharma, J.M., 2002b. The role of T cells in protection by an inactivated infectious bursal disease virus vaccine. Vet. Immunol. Immunopathol. 89, 159-167. Repp, H., Nieper, H., Draheim, H.J., Koschinski, A., Muller, H., Dreyer, F., 1998. Infectious bursal disease virus changes the potassium current properties of chicken embryo fibroblasts. Virology. 246, 362-369. Rogel, A., Benvenisti, L., Sela, I., Edelbaum, O., Tanne, E., Shachar, Y., Zanberg, Y., Gontmakher, T., Khayat, E., Stram, Y., 2003. Vaccination with E. coli recombinant empty viral particles of infectious bursal disease virus (IBDV) confer protection. Virus Genes. 27, 169-175. Rong, J., Jiang, T., Cheng, T., Shen, M., Du, Y., Li, S., Wang, S., Xu, B., Fan, G., 2007. Large-scale manufacture and use of recombinant VP2 vaccine against infectious bursal disease in chickens. Vaccine. 25, 7900-7908. Rosenberger, J.K., Cloud, S.S., 1986. Isolation and characterization of variant infectious bursal disease viruses. Proceedings of the 123rd Annual meeting of the American Veterinary Medical Association, Abstract no. 181. Sanchez, A.B., Rodriguez, J.F., 1999. Proteolytic processing in infectious bursal disease virus: identification of the polyprotein cleavage sites by site-directed mutagenesis. Virology. 262, 190-199. Sapats, S.I., Ignjatovic, J., 2000. Antigenic and sequence heterogeneity of infectious bursal disease virus strains isolated in Australia. Arch. Virol. 145, 773-785. Schijns, V.E.J.C., Sharma, J., Tarpy, I. 2008. Practical aspects of poultry vaccination, In: Davison, F., Kaspers, B., Schat, K.A. (Eds.) Avian Immunology 1st edn. Academic Press, 373-393. Schirmbeck, R., Melber, K., Mertens, T., Reimann, J., 1994. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 68, 1418-1425. Sharma, J.M., Dohms, J.E., Metz, A.L., 1989. Comparative pathogenesis of serotype 1 and variant serotype 1 isolates of infectious bursal disease virus and their effect on humoral and cellular immune competence of specific-pathogen-free chickens. Avian Dis. 33, 112-124. Sharma, J.M., Kim, I.J., Rautenschlein, S., Yeh, H.Y., 2000. Infectious bursal disease virus of chickens: pathogenesis and immunosuppression. Dev. Comp. Immunol. 24, 223-235. Sivakumar, S.M., Safhi, M.M., Kannadasan, M., Sukumaran, N., 2011. Vaccine adjuvants - Current status and prospects on controlled release adjuvancity. Saudi Pharm. J. 19, 197-206. Snyder, D.B., 1990. Changes in the field status of infectious bursal disease virus. Avian Pathol. 19, 419-423. Snyder, D.B., Lana, D.P., Savage, P.K., Yancey, F.S., Mengel, S.A., Marquardt, W.W., 1988. Differentiation of infectious bursal disease viruses directly from infected tissues with neutralizing monoclonal antibodies: evidence of a major antigenic shift in recent field isolates. Avian Dis. 32, 535-539. Spies, U., Muller, H., Becht, H., 1987. Properties of RNA polymerase activity associated with infectious bursal disease virus and characterization of its reaction products. Virus Res. 8, 127-140. Straw, B.E., MacLachlan, N.J., Corbett, W.T., Carter, P.B., Schey, H.M., 1985. Comparison of tissue reactions produced by Haemophilus pleuropneumoniae vaccines made with six different adjuvants in swine. Can. J. Comp. Med. 49, 149-151. Streatfield, S.J., Jilka, J.M., Hood, E.E., Turner, D.D., Bailey, M.R., Mayor, J.M., Woodard, S.L., Beifuss, K.K., Horn, M.E., Delaney, D.E., Tizard, I.R., Howard, J.A., 2001. Plant-based vaccines: unique advantages. Vaccine. 19, 2742-2748. Taghavian, O., Spiegel, H., Hauck, R., Hafez, H.M., Fischer, R., Schillberg, S., 2013. Protective oral vaccination against infectious bursal disease virus using the major viral antigenic protein VP2 produced in Pichia pastoris. PLoS One. 8, e83210. Triozzi, P., Gochnour, D., Martin, E., Aldrich, W., Powell, J., Kim, J., Young, D., Lombardi, J., 1994. Clinical and immunological effects of a synthetic Beta-human chorionic-gonadotropin vaccine. Int. J. Oncol. 5, 1447-1453. Tsukamoto, K., Obata, H., Hihara, H., 1990. Improved preparation of ELISA antigen of infectious bursal disease virus. Avian Dis. 34, 209-213. Tsukamoto, K., Tanimura, N., Hihara, H., Shirai, J., Imai, K., Nakamura, K., Maeda, M., 1992. Isolation of virulent infectious bursal disease virus from field outbreaks with high mortality in Japan. J. Vet. Med. Sci. 54, 153-155. Tsukamoto, K., Tanimura, N., Mase, M., Imai, K., 1995. Comparison of virus replication efficiency in lymphoid tissues among three infectious bursal disease virus strains. Avian Dis. 39, 844-852. Turner, J.L., Trauger, R.J., Daigle, A.E., Carlo, D.J., 1994. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS. 8, 1429-1435. Vakharia, V.N., Snyder, D.B., He, J., Edwards, G.H., Savage, P.K., Mengel-Whereat, S.A., 1993. Infectious bursal disease virus structural proteins expressed in a baculovirus recombinant confer protection in chickens. J. Gen. Virol. 74, 1201-1206. van den Berg, T.P., Gonze, M., Meulemans, G., 1991. Acute infectious bursal disease in poultry: isolation and characterisation of a highly virulent strain. Avian Pathol. 20, 133 - 143. Vogel, F.R., Powell, M.F. 1996. A compendium of vaccine adjuvants and excipients, In: Powell, M.F., Newman, M.J. (Eds.) Vaccine Design: the Subunit and Adjuvant Approach. Plenum Press, New York, 141-228. Walls, R.S., 1977. Eosinophil response to alum adjuvants: involvement of T cells in non-antigen-dependent mechanisms. Proc. Soc. Exp. Biol. Med. 156, 431-435. Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., Felgner, P.L., 1990. Direct gene transfer into mouse muscle in vivo. Science. 247, 1465-1468. Wood, G.W., Muskett, J.C., Thornton, D.H., 1981. The interaction of live vaccine and maternal antibody in protection against infectious bursal disease. Avian Pathol. 10, 365-373. Wu, H., Singh, N.K., Locy, R.D., Scissum-Gunn, K., Giambrone, J.J., 2004. Immunization of chickens with VP2 protein of infectious bursal disease virus expressed in Arabidopsis thaliana. Avian Dis. 48, 663-668. Wyeth, P.J., Cullen, G.A., 1976. Maternally derived antibody--effect on susceptibility of chicks to infectious bursal disease. Avian Pathol. 5, 253-260. Yeh, H.Y., Rautenschlein, S., Sharma, J.M., 2002. Protective immunity against infectious bursal disease virus in chickens in the absence of virus-specific antibodies. Vet. Immunol. Immunopathol. 89, 149-158. Young, S.L., Wilson, M., Wilson, S., Beagley, K.W., Ward, V., Baird, M.A., 2006. Transcutaneous vaccination with virus-like particles. Vaccine. 24, 5406-5412.
摘要: Infectious bursal disease virus (IBDV) causing infectious bursal disease (IBD), a contagious and immunosuppressive disease of young chickens, is one of the most economically significant viruses of poultry worldwide. The major neutralization epitopes of IBDV is located on the viral structure protein VP2. Live attenuated vaccine was usually used to control IBD. However, it causes side-effects such as moderate to severe bursal lesions. The young chickens on farms are protected against IBD by maternal antibody for the first couple weeks post hatch. The objective of this study is to investigate the efficacy of a subunit vaccine containing VP2 protein in chickens with maternal antibody through different vaccination programs. The recombinant VP2 protein was expressed by E. coli and confirmed by western blot. The recombinant protein mixed with Freund's adjuvant (FA) or ISA 71 as subunit vaccines were used for four animal trials. Enzyme-linked immunosorbent assay (ELISA) titers and virus neutralization (VN) titers of anti-IBDV antibodies were measured for collected chicken sera. All chickens were challenged at 28 days of age and observed for 5 days, and bursal gross lesion scores (BGLS) and bursal histopathological lesion scores (BHLS) were given to each chicken. Protections were evaluated according to the mortality, BGLS and BHLS. The results of animal Trial I and II indicated that the subunit vaccine mixed with ISA 71 and delivered by subcutaneous (SC) route was able to provide 100 % of protection against IBDV challenge in SPF chickens. The results of animal Trial III and IV indicated that the subunit vaccine mixed with ISA 71 and delivered by SC route twice at 7 (or 10) and 18 days of age provided 100 % protection against IBDV challenge in chickens with maternal antibody. In conclusion, the subunit vaccine containing IBDV VP2 protein protected chickens with maternal antibody against vvIBDV challenge.
雞傳染性華氏囊病 (infectious bursal disease; IBD) 是由雞傳染性華氏囊病毒 (infectious bursal disease virus; IBDV) 感染年輕雞隻引起的高度傳染性免疫抑制疾病,會提高雞隻對其他疾病的感受性,造成全球雞禽養殖業者嚴重的經濟損失。IBDV的VP2蛋白是感染宿主免疫產生中和抗體的關鍵。雖然透過施打活減毒疫苗可以控制IBD疫情,但會造成華氏囊損傷。本篇之研究目的是使用具有母源抗體的雞隻,以皮下注射的免疫方式,搭配不同的免疫時程,評估混合市售ISA 71佐劑之IBD次單位疫苗的保護力。本篇次單位疫苗中重組可溶蛋白來自大腸桿菌所表現之IBDV polyprotein,以西方墨點法確認目標蛋白,搭配混合市售ISA 71佐劑來進行動物實驗,並以注射PBS為陰性對照組 (NC),免疫混合佛氏佐劑之次單位疫苗或市售不活化疫苗為疫苗對照組。所有雞隻都在28日齡時進行攻毒試驗,觀察5日後進行犧牲剖檢,根據華氏囊的肉眼病變、組織學病變及死亡率來評估疫苗的保護力。雞隻血清以ELISA和病毒中和性試驗 (VN assay) 測定IBDV抗體力價。共完成了四次動物實驗,在動物實驗一與二的結果中,混合市售ISA 71佐劑之次單位疫苗組 (SV) 的注射路徑由肌肉注射改成皮下注射,仍維持有100 % 的保護力。由此可知,混合市售ISA 71佐劑之次單位疫苗以皮下注射之免疫方式,能夠保護雞隻避免IBDV感染。在動物實驗三與四的結果中,在1和14日齡時免疫混合市售ISA 71佐劑之次單位疫苗組只有33 % 的保護力,但在7 (或10) 和18日齡時免疫混合市售ISA 71佐劑之次單位疫苗組都有100 % 的保護力。綜合以上結果,在適當的免疫時程下,含有VP2蛋白並混合市售ISA 71佐劑之次單位疫苗可以保護具有母源抗體雞隻避免IBDV感染。
URI: http://hdl.handle.net/11455/93094
文章公開時間: 2018-08-25
Appears in Collections:微生物暨公共衛生學研究所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.